RPG Life Sciences Limited — Earnings Release 2022

Jan 25, 2022

==> picture [506 x 98] intentionally omitted <==

January 25, 2022

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, ‘G’ Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051.

BSE Limited Corporate Relationship Department Floor 25, P.J. Towers Dalal Street Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2021.

Kindly take the above on record.

Thanking you,

Yours faithfully, For RPG Life Sciences Limited Rajesh Shirambekar Head – Legal & Company Secretary Encl: as above

==> picture [73 x 72] intentionally omitted <==

==> picture [531 x 56] intentionally omitted <==

==> picture [81 x 40] intentionally omitted <==

Q3 FY22 Revenue from operations grew by 7% and PBT grew by 21% Y‐o‐Y 9M FY22 Revenue from operations grew by 13% and PBT grew by 39% with EBITDA margin expanding from 19.5% to 22.2% Y‐o‐Y

Mumbai, 25 January, 2022 : RPG Life Sciences Limited has announced its financial results for the third quarter and nine months ended December 31, 2021.

Q3 FY22 Highlights	Y‐o‐Y Revenue from operations	Y‐o‐Y PBT
	Rs 115.58 crores – up from Rs 107.60 crores	Rs 20.62 crores – up from Rs 17.07 crores
9M FY22 Highlights	Rs 336.36 crores – up from Rs 296.38 crores	Rs 62.24 crores – up from Rs 44.63 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT by 21% Y‐o‐Y for Q3 FY22, maintaining the upward trajectory in EBITDA margins, which improved from 19.9% to 21.4% Y‐o‐Y. Revenue from operations at Rs 115.58 crores registered a growth of 7% Y‐o‐Y for Q3 FY22. For 9M FY22, the company posted a jump in PBT by 39% Y‐o‐Y and recorded EBITDA margin expansion from 19.5% to 22.2% Y‐o‐Y. Revenue from operations at Rs 336.36 crores registered a growth of 13% Y‐o‐Y for 9M FY22.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “I am pleased to share that in Q3 FY22, we continued to deliver a robust performance. Revenue and PBT grew by 7% and 21% respectively Y‐o‐Y. EBITDA margins’ upward trajectory continued, growing from 19.9% to 21.4% Y‐o‐Y. The Company continues to remain debt free with highest‐ever net cashflow generated from operations in 9M FY22.

Domestic Formulations business recorded a robust growth both in value and volumes ‐ significantly better than the market. While life cycle management initiatives helped legacy brands register healthy growth, our new product portfolio is also witnessing an impressive uptake. We have successfully forayed into a new segment ‐ Rheumatology, which is strengthening our endeavour of expanding into the Specialty segment. Salesforce productivity continues to register upward momentum. API business also recorded robust growth. In the International Formulations business, our growth was somewhat subdued due to the political unrest in one of our key markets, Myanmar. However, rest of the international business reflected strong performance supported by new launches. Going forward, we stay committed to implementing our Transformation Agenda to grow both topline and bottomline across segments.”

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research‐based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

RPG Enterprises, established in 1979, is one of India’s fastest growing business groups with a turnover of US$ 4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation‐led technology businesses.

==> picture [134 x 28] intentionally omitted <==

Media Contact: Sumeet Chatterjee Senior Vice President – Corporate Brand and Group Communications +91 9820340650 | sumeet@rpg.in